IP Library Granted Patent US 9,175,263
Granted Patent B2
US 9,175,263 · App. 13/972,695 · Granted Nov 3, 2015

Methods and compositions for targeting progenitor cell lines

Inventors: David Larocca (Encinitas, CA); Paola Bignone (San Diego, CA); Michael West (Mill Valley, CA); Evan Snyder (La Jolla, CA)
C12N5/0606C07K7/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,175,263
App. No.
13/972,695
Granted
Nov 3, 2015
Kind
B2
Abstract

The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.

Claims (12)

1. A peptide that binds to a progenitor cell wherein the peptide is selected from the group consisting of peptides comprising the following sequences: SWTYSYPNQNMD (SEQ ID NO: 1); DWTYSLPGLVEE (SEQ ID NO: 2); NWTWSMPTGNPA (SEQ ID NO: 3); GMTLRVLTN-YTE- (SEQ ID NO: 4); TLHVSENSWTYN (SEQ ID NO: 5); DWLWSFAPNVDT (SEQ ID NO: 6); TLSSQNPYMHKK (SEQ ID NO: 7); IDKQMMTSHKAI (SEQ ID NO: 8); QGMETQKLRMLK (SEQ ID NO: 9); GWYWETPLDMFN (SEQ ID NO: 10); GWVIDYDYYPMR (SEQ ID NO: 11); VTAENYQSFSVS (SEQ ID NO: 12); NNKMDDRMMMSIV (SEQ ID NO: 13); STGTDLHSNARI (SEQ ID NO: 14); YEFDNLLNRTLW (SEQ ID NO: 15); and EWTVNERTMWDL (SEQ ID NO: 16).

2. The peptide of claim 1 , wherein the peptide has plexin homology.

3. A composition comprising a progenitor cell and a peptide specifically bound to the progenitor cell, wherein the progenitor cell is the in vitro progeny of a pluripotent stem cell, and wherein the peptide has a length of 8-35 amino acids.

4. The composition of claim 3 , wherein the progenitor cell is a human progenitor cell.

5. The composition of claim 4 , wherein the progenitor cell is an endoderm progenitor cell.

6. The composition of claim 4 , wherein the progenitor cell is a mesoderm progenitor cell.

7. The composition of claim 3 , wherein the progenitor cell is the W10 progenitor cell.

8. The composition of claim 3 , wherein the progenitor cell expresses the markers heart and neural crest derivatives-expressed 2 (HAND2), HOXA4 and HOXB7.

9. The composition of claim 3 , wherein the peptide is selected from the group consisting of peptides comprising the following sequences: SWTYSYPNQNMD (SEQ ID NO: 1); DWTYSLPGLVEE (SEQ ID NO: 2); NWTWSMPTGNPA (SEQ ID NO: 3); GMTLRVLTN-YTE- (SEQ ID NO: 4); TLHVSENSWTYN (SEQ ID NO: 5); DWLWSFAPNVDT (SEQ ID NO: 6); TLSSQNPYMHKK (SEQ ID NO: 7); IDKQMMTSHKAI (SEQ ID NO: 8); QGMETQKLRMLK (SEQ ID NO: 9); GWYWETPLDMFN (SEQ ID NO: 10); GWVIDYDYYPMR (SEQ ID NO: 11); VTAENYQSFSVS (SEQ ID NO: 12); NNKMDDRMMMSIV (SEQ ID NO: 13); STGTDLHSNARI (SEQ ID NO: 14); YEFDNLLNRTLW (SEQ ID NO: 15); and EWTVNERTMWDL (SEQ ID NO: 16).

10. The composition of claim 3 , wherein the peptide has plexin homology.

11. The composition of claim 3 , wherein the peptide comprises a detectable substance.

12. The composition of claim 11 , wherein the detectable substance is an amino acid sequence.

Assignments (1)
CHANGE OF NAME Recorded Oct 1, 2020
From: BIOTIME INC.
To: LINEAGE CELL THERAPEUTICS, INC.
Reel/Frame 053955/0777 →
Continuity (3)
Provisional Application 61692139 · Aug 22, 2012
Provisional Application 61769119 · Feb 25, 2013
Related Publication 20140099712A1 · Apr 10, 2014